PTCT Quote, Financials, Valuation and Earnings

Amicus Therapeutics has a net margin of -30.91% compared to PTC Therapeutics's net margin of 9.85%. PTC Therapeutics's return on equity of -- beat Amicus Therapeutics's return on equity of -35.23%.

PTC Therapeutics has a consensus price target of $64.93, signalling upside risk potential of 22.25%. On the other hand Amicus Therapeutics has an analysts' consensus of $16.73 which suggests that it could grow by 89.87%. Given that Amicus Therapeutics has higher upside potential than PTC Therapeutics, analysts believe Amicus Therapeutics is more attractive than PTC Therapeutics.

PTC Therapeutics has a beta of 0.660, which suggesting that the stock is 34.007% less volatile than S&P 500. In comparison Amicus Therapeutics has a beta of 0.690, suggesting its less volatile than the S&P 500 by 30.977%.

PTC Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics pays -- of its earnings as a dividend. Amicus Therapeutics pays out -- of its earnings as a dividend.

PTC Therapeutics quarterly revenues are $213.2M, which are larger than Amicus Therapeutics quarterly revenues of $149.7M. PTC Therapeutics's net income of -$65.9M is lower than Amicus Therapeutics's net income of $14.7M. Notably, PTC Therapeutics's price-to-earnings ratio is -- while Amicus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics is 5.03x versus 5.08x for Amicus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Olema Pharmaceuticals has a net margin of -30.91% compared to PTC Therapeutics's net margin of --. PTC Therapeutics's return on equity of -- beat Olema Pharmaceuticals's return on equity of --.

PTC Therapeutics has a consensus price target of $64.93, signalling upside risk potential of 22.25%. On the other hand Olema Pharmaceuticals has an analysts' consensus of $28.00 which suggests that it could grow by 540.73%. Given that Olema Pharmaceuticals has higher upside potential than PTC Therapeutics, analysts believe Olema Pharmaceuticals is more attractive than PTC Therapeutics.

PTC Therapeutics has a beta of 0.660, which suggesting that the stock is 34.007% less volatile than S&P 500. In comparison Olema Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

PTC Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Olema Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics pays -- of its earnings as a dividend. Olema Pharmaceuticals pays out -- of its earnings as a dividend.

PTC Therapeutics quarterly revenues are $213.2M, which are larger than Olema Pharmaceuticals quarterly revenues of --. PTC Therapeutics's net income of -$65.9M is lower than Olema Pharmaceuticals's net income of -$34.6M. Notably, PTC Therapeutics's price-to-earnings ratio is -- while Olema Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics is 5.03x versus -- for Olema Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -30.91% compared to PTC Therapeutics's net margin of 31.35%. PTC Therapeutics's return on equity of -- beat Vertex Pharmaceuticals's return on equity of -3.23%.

PTC Therapeutics has a consensus price target of $64.93, signalling upside risk potential of 22.25%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $496.70 which suggests that it could grow by 0.26%. Given that PTC Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe PTC Therapeutics is more attractive than Vertex Pharmaceuticals.

PTC Therapeutics has a beta of 0.660, which suggesting that the stock is 34.007% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.629%.

PTC Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

PTC Therapeutics quarterly revenues are $213.2M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.9B. PTC Therapeutics's net income of -$65.9M is lower than Vertex Pharmaceuticals's net income of $913M. Notably, PTC Therapeutics's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics is 5.03x versus 11.66x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Voyager Therapeutics has a net margin of -30.91% compared to PTC Therapeutics's net margin of -549.33%. PTC Therapeutics's return on equity of -- beat Voyager Therapeutics's return on equity of -21.07%.

PTC Therapeutics has a consensus price target of $64.93, signalling upside risk potential of 22.25%. On the other hand Voyager Therapeutics has an analysts' consensus of $16.10 which suggests that it could grow by 296.55%. Given that Voyager Therapeutics has higher upside potential than PTC Therapeutics, analysts believe Voyager Therapeutics is more attractive than PTC Therapeutics.

PTC Therapeutics has a beta of 0.660, which suggesting that the stock is 34.007% less volatile than S&P 500. In comparison Voyager Therapeutics has a beta of 0.991, suggesting its less volatile than the S&P 500 by 0.87699999999999%.

PTC Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Voyager Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics pays -- of its earnings as a dividend. Voyager Therapeutics pays out -- of its earnings as a dividend.

PTC Therapeutics quarterly revenues are $213.2M, which are larger than Voyager Therapeutics quarterly revenues of $6.3M. PTC Therapeutics's net income of -$65.9M is lower than Voyager Therapeutics's net income of -$34.5M. Notably, PTC Therapeutics's price-to-earnings ratio is -- while Voyager Therapeutics's PE ratio is 6.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics is 5.03x versus 2.93x for Voyager Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.